GT200200038A - Conjugados peg de hgf-nk4 - Google Patents

Conjugados peg de hgf-nk4

Info

Publication number
GT200200038A
GT200200038A GT200200038A GT200200038A GT200200038A GT 200200038 A GT200200038 A GT 200200038A GT 200200038 A GT200200038 A GT 200200038A GT 200200038 A GT200200038 A GT 200200038A GT 200200038 A GT200200038 A GT 200200038A
Authority
GT
Guatemala
Prior art keywords
hgf
conjugates
peg conjugates
peg
hepatocits
Prior art date
Application number
GT200200038A
Other languages
English (en)
Inventor
Michael Brandt
Apollon Papadimitriou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200038A publication Critical patent/GT200200038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A CONJUGADOS DEL FRAGMENTO TERMINAL, QUE CONTIENE CUATRO DOMINIOS "KRINGLE", DEL FACTOR DE CRECIMIENTO DE LOS HEPATOCITOS (NK4), CON POLIETILENGLICOL (PEG) DE FORMULA (I) EN DONDE P, X, M, R, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. LOS CONJUGADOS SON DE PROPIEDADES PERFECCIONADAS Y DE UTILIDAD EN TUMORES.
GT200200038A 2001-02-23 2002-02-22 Conjugados peg de hgf-nk4 GT200200038A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4

Publications (1)

Publication Number Publication Date
GT200200038A true GT200200038A (es) 2002-09-30

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200038A GT200200038A (es) 2001-02-23 2002-02-22 Conjugados peg de hgf-nk4

Country Status (27)

Country Link
US (2) US20030012775A1 (es)
EP (2) EP1234583A1 (es)
JP (2) JP2004521139A (es)
KR (2) KR20030072629A (es)
CN (1) CN100339393C (es)
AR (1) AR032574A1 (es)
AU (1) AU2002233354B2 (es)
BG (1) BG108125A (es)
BR (1) BR0207510A (es)
CA (1) CA2438308A1 (es)
CZ (1) CZ20032511A3 (es)
EC (1) ECSP034741A (es)
GT (1) GT200200038A (es)
HR (1) HRP20030659A2 (es)
HU (1) HUP0400979A2 (es)
IL (1) IL157426A0 (es)
MA (1) MA26998A1 (es)
MX (1) MXPA03007130A (es)
NO (1) NO20033737L (es)
PA (1) PA8540501A1 (es)
PE (1) PE20020992A1 (es)
PL (1) PL367402A1 (es)
RU (1) RU2293574C2 (es)
SK (1) SK11652003A3 (es)
WO (1) WO2002074344A2 (es)
YU (1) YU65103A (es)
ZA (1) ZA200306080B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
JP2007525981A (ja) 2004-03-03 2007-09-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法
JP4511589B2 (ja) 2004-03-03 2010-07-28 エフ．ホフマン−ラ ロシュ アーゲー 肝細胞成長因子のｎ末端フラグメントを精製するための方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
JP5579164B2 (ja) * 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
JPWO2020158690A1 (ja) * 2019-01-28 2021-12-16 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
BR112021012472A2 (pt) * 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222603T1 (de) 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
GEP20002180B (en) * 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
RU2158603C2 (ru) * 1994-05-31 2000-11-10 Амген Инк. Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
EP0816381B1 (en) * 1995-03-10 2004-01-14 NAKAMURA, Toshikazu Polyethylene glycol modified hepatocyte growth factor (hgf)
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
ATE342729T1 (de) 1997-01-15 2006-11-15 Phoenix Pharmacologics Inc Modifizierter tumor-nekrosefaktor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
EE05214B1 (et) * 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2002233230B2 (en) * 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates

Also Published As

Publication number Publication date
BR0207510A (pt) 2004-07-27
ECSP034741A (es) 2003-10-28
EP1234583A1 (en) 2002-08-28
HRP20030659A2 (en) 2004-08-31
HUP0400979A2 (hu) 2004-08-30
RU2003127395A (ru) 2005-03-20
MA26998A1 (fr) 2004-12-20
ZA200306080B (en) 2004-11-23
CZ20032511A3 (en) 2004-03-17
CN1571679A (zh) 2005-01-26
MXPA03007130A (es) 2003-11-18
CA2438308A1 (en) 2002-09-26
PL367402A1 (en) 2005-02-21
JP2010174034A (ja) 2010-08-12
US20030012775A1 (en) 2003-01-16
EP1389132A2 (en) 2004-02-18
NO20033737D0 (no) 2003-08-22
SK11652003A3 (sk) 2004-05-04
BG108125A (bg) 2004-09-30
CN100339393C (zh) 2007-09-26
US20080085857A1 (en) 2008-04-10
RU2293574C2 (ru) 2007-02-20
JP2004521139A (ja) 2004-07-15
KR20030072629A (ko) 2003-09-15
IL157426A0 (en) 2004-03-28
PA8540501A1 (es) 2002-09-30
WO2002074344A2 (en) 2002-09-26
YU65103A (sh) 2006-03-03
US7846896B2 (en) 2010-12-07
AR032574A1 (es) 2003-11-12
NO20033737L (no) 2003-10-21
PE20020992A1 (es) 2002-11-01
KR20090020713A (ko) 2009-02-26
AU2002233354B2 (en) 2006-11-30
WO2002074344A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
GT200200038A (es) Conjugados peg de hgf-nk4
CO5180590A1 (es) Derivados de camptotecina que tienen actividad anti tumores
ATE246202T1 (de) Gcsf konjugate
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
CY1117029T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
NO881639D0 (no) Stjerneformede konjugater.
DE60024581D1 (de) 6-phenylphenanthridine mit pde-iv hemmender wirkung
DK1568772T3 (da) Varianter af humant væksthormon
DE60122335D1 (de) Zusammensetzung auf der basis polymerer mizellen
DK1028753T4 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydelige hydrogeler
ES2170102T3 (es) Aminociclohexilesteres y utilizacion de los mismos.
ATE328958T1 (de) Hdpe polymerzusammensetzung
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CY1110233T1 (el) Συμπλοκο συντονισμου του διαμινοκυκλοεξανο λευκοχρυσου(ιι) με μπλοκ συμπολυμερες που περιεχει τμημα πολυ(καρβοξυλικου οξεος) και παραγοντα κατα του ογκου που περιλαμβανει αυτο
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
AR027355A1 (es) Acidos tiazolidincarboxilicos
DE50105640D1 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
SE0004245D0 (sv) Novel compounds and their use
TR200003144T2 (tr) Tiyenopirimidinler.
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
SE0003476D0 (sv) Compounds
DE60025327D1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
DE60001568D1 (de) Benzopyrane, anneliert via c7-c8 mit einem aromatischen heterocyclus und diese enthaltende zubereitungen und (co)polymer matrices
PT1204659E (pt) Benzofuranos serotoninergicos